^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tyvyt (sintilimab)

    i
    Other names: IBI308, IBI 308, IBI-308, LY-3342901
    Company:
    Eli Lilly, Innovent Biologics, Mankind Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    22h
    HCC-IM-1: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    24h
    NIBCUN: Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • carboplatin • Tyvyt (sintilimab) • pemetrexed
    1d
    SCENT-3: Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Sun Yat-sen University
    New trial
    |
    Tyvyt (sintilimab) • azacitidine • oxaliplatin • Epidaza (chidamide)
    5d
    Denosumab Strategy for Liver Cancer With Bone Metastases (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Tongji Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Prolia (denosumab)
    5d
    Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Tongji Hospital
    New P3 trial
    |
    Tyvyt (sintilimab) • Lenvima (lenvatinib)
    5d
    CHANCE2202: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (clinicaltrials.gov)
    P=N/A, N=941, Completed, Zhongda Hospital | Recruiting --> Completed | N=220 --> 941 | Trial completion date: Sep 2023 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Zepsun (donafenib)
    5d
    Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment (clinicaltrials.gov)
    P=N/A, N=200, Completed, Sun Yat-sen University
    New trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib)
    5d
    BEST: SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=58, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    5d
    LUCENT-GC-02: Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer (clinicaltrials.gov)
    P2, N=108, Recruiting, Qilu Hospital of Shandong University
    New P2 trial
    |
    Tyvyt (sintilimab) • oxaliplatin
    5d
    CHANCE2201: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (clinicaltrials.gov)
    P=N/A, N=1244, Completed, Zhongda Hospital | Recruiting --> Completed | N=474 --> 1244
    Trial completion • Enrollment change
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Zepsun (donafenib)
    6d
    A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (clinicaltrials.gov)
    P2/3, N=680, Recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin • Tabosun (ipilimumab N01 injection)
    7d
    MET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report. (PubMed, Transl Lung Cancer Res)
    The disease proved refractory to multiple lines of therapy, including platinum-based chemotherapy, immunotherapy, intrathoracic instillation and a subsequent individualized regimen comprising intraperitoneal cisplatin plus sintilimab for local disease control and potential immunomodulation synergized with oral anlotinib. It illustrates that rare but actionable genomic alterations, such as MET amplification, can be identified through liquid or tissue biopsy and can inform successful targeted treatment strategies, even in a tumor type where such alterations are uncommon. Histological classification combined with molecular profiling remains pivotal for personalized oncology.
    Journal • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1)
    |
    MET amplification • MET mutation
    |
    cisplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • Orpathys (savolitinib)